Substance Use Disorder (SUD)NCT03220373
Predicting Dropout and Outcome From Neuropsychological Functions in SUD Patients
An observational study of Substance Use Disorder (SUD), run by Oslo University Hospital at 1 site in Norway.
Trial summary
The aim of this project is to gain a more specific understanding of how different cognitive profiles predict residential treatment drop-out, treatment retention and post-treatment outcome in a population with Substance Use Disorder. Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- Substance Use Disorder (SUD)
- How many people
- 200 participants
- Where
- 1 siteNorway
- Study dates
- 7 Mar 2017to 31 Dec 2029
- How long will I take part?
- 1 Year
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- Adult, Older adult
Study population: Treatment seeking Substance Use Disorder (SUD) patients.
Who may be able to join
- Substance Use Disorder (SUD) patients.
- 18 years or older.
- Qualified to consent to research participation.
- Able to speak and write in Norwegian.
Who cannot join
- Not qualified to consent to research participation.
- Insufficient understanding of Norwegian.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Predicting Early Treatment Termination (Dropout) and Post-treatment Clinical Outcome From Neuropsychological Functions in Abstinent Substance Use Dependent (SUD) Patients
The aim of this project is to gain a more specific understanding of how different cognitive profiles predict residential treatment drop-out, treatment retention and post-treatment outcome in a population with Substance Use Disorder.
Read the detailed description
This project collects the neuropsychological profile of residential SUD patients, in addition to treatment length, exit reason, hospital journal data and post-treatment clinical outcome data. The project aims to identify clinically relevant neurocognitive domains that predict treatment dropout and post-treatment clinical outcome. This will make it possible for future clinicians to focus their effort on neurocognitive functions most relevant for this particular patient group.
RESEARCH QUESTIONS:
- What neurocognitive domain (and sub-domain) are the strongest predictor of treatment drop-out and retention?
- What neurocognitive domain (and sub-domain) are the strongest predictor of post-treatment clinical outcome variables such as drug use, health and social integration.
- Will data on treatment length, age, gender, substance abuse history or psychiatric co-morbidity predict outcome independently, or in interaction with, the neuropsychological profile?
This longitudinal prospective cohort study aims for a continuous collection of neuropsychological data baseline and post-treatment follow-up data until 2030.
- Conditions
- Substance Use Disorder (SUD)
- Keywords
- Neuropsychology, Cognition, Drop-out, Follow-up
- Medical subject headings
- Substance-Related Disorders
What is being measured
The primary outcome is the main question the study is designed to answer.
Exit reason
Reason for terminating residential SUD treatment (Treatment completed or Drop-out)
Measured: On average 3 months
Treatment retention
Number of days in treatment
Measured: On average 3 months
Secondary outcomes (6)
Substance use
DUDIT (Drug Use Disorders Identification Test)
Measured: 1 year after neuropsychological assessment
Psychological distress
SCL-10 (Symptom Checklist)
Measured: 1 year after neuropsychological assessment
Quality of Life
QoL-5 (Quality of Life)
Measured: 1 year after neuropsychological assessment
ADHD symptoms
ASRS (ADHD Self-Report Scale)
Measured: 1 year after neuropsychological assessment
Income
Nature of income
Measured: 1 year after neuropsychological assessment
Housing
Nature of present accommodation
Measured: 1 year after neuropsychological assessment
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Jul 2017
- Study start7 Mar 2017
- Primary completion31 Dec 2029 (estimated)
- Study completion31 Dec 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Substance Use Disorder (SUD)Studies of the same condition, open and under way.
- More trials run by Oslo University HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 200 participants (estimated)
- Target duration
- 1 Year
Sponsor and investigators
- Lead sponsor
- Oslo University Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Espen Walderhaug, Oslo University Hospital
- Investigators
- Espen Walderhaug, PhD, Principal investigator, Oslo University Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03220373
- Sponsor's protocol ID
- 2015/11288
- Other IDs
- 2015
- Status last verified
- Oct 2026
- First submitted
- 8 Mar 2017
- Last updated
- 26 Oct 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 26 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Predicting Early Treatment Termination (Dropout) and Post-treatment Clinical Outcome From Neuropsychological Functions in Abstinent Substance Use Dependent (SUD) Patients
- ClinicalTrials.gov ID
- NCT03220373
- Acronym / sponsor ID
- 2015/11288
- Conditions
- Substance Use Disorder (SUD)
- Keywords
- Neuropsychology, Cognition, Drop-out, Follow-up
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 200 participants (estimated)
- Lead sponsor
- Oslo University HospitalUniversity, hospital or other
- Study start
- 7 Mar 2017 (actual)
- Primary completion
- 31 Dec 2029 (estimated)
- Study completion
- 31 Dec 2029 (estimated)
- First posted
- 18 Jul 2017 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of this project is to gain a more specific understanding of how different cognitive profiles predict residential treatment drop-out, treatment retention and post-treatment outcome in a population with Substance Use Disorder.
Detailed description
This project collects the neuropsychological profile of residential SUD patients, in addition to treatment length, exit reason, hospital journal data and post-treatment clinical outcome data. The project aims to identify clinically relevant neurocognitive domains that predict treatment dropout and post-treatment clinical outcome. This will make it possible for future clinicians to focus their effort on neurocognitive functions most relevant for this particular patient group.
RESEARCH QUESTIONS:
- What neurocognitive domain (and sub-domain) are the strongest predictor of treatment drop-out and retention?
- What neurocognitive domain (and sub-domain) are the strongest predictor of post-treatment clinical outcome variables such as drug use, health and social integration.
- Will data on treatment length, age, gender, substance abuse history or psychiatric co-morbidity predict outcome independently, or in interaction with, the neuropsychological profile?
This longitudinal prospective cohort study aims for a continuous collection of neuropsychological data baseline and post-treatment follow-up data until 2030.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 1 Year
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Age groups
- Adult, Older adult
- Study population
- Treatment seeking Substance Use Disorder (SUD) patients.
Key inclusion criteria (4 listed)
- Substance Use Disorder (SUD) patients.
- 18 years or older.
- Qualified to consent to research participation.
- Able to speak and write in Norwegian.
Key exclusion criteria (2 listed)
- Not qualified to consent to research participation.
- Insufficient understanding of Norwegian.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Exit reason
Time frame: On average 3 months
Reason for terminating residential SUD treatment (Treatment completed or Drop-out)
Treatment retention
Time frame: On average 3 months
Number of days in treatment
6 secondary outcomes
Substance use
Time frame: 1 year after neuropsychological assessment
Psychological distress
Time frame: 1 year after neuropsychological assessment
Quality of Life
Time frame: 1 year after neuropsychological assessment
ADHD symptoms
Time frame: 1 year after neuropsychological assessment
Income
Time frame: 1 year after neuropsychological assessment
Housing
Time frame: 1 year after neuropsychological assessment
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 Oct 2026.
Related trials for Substance Use Disorder (SUD)
Recruiting
Fighting Addictions, Improving Lives: COmprehensive Drug Rehabilitation With Music
Substance Use Disorder (SUD)
Enrolling by invitation
Incentives and Long-Acting Injectable Adherence After Involuntary Hospitalization
Schizophrenia Disorder, Schizoaffective Disorder
Not yet recruitingEarly Phase 1
Research Investigating Drug Effects-2 (RiDE-2)
Cannabis Use, Substance Use Disorder (SUD)
Enrolling by invitationObservational study
Research and Engagement on Substance Use: Harnessing Awareness and Personalized Education (RESHAPE) to Improve Well-being and Self-efficacy
Substance Use Disorder (SUD)
Not yet recruitingObservational study
Disease Intervention Specialist (DIS) for SUD
Substance Use Disorder (SUD), Opioid Use Disorder
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Espen Walderhaug, PhD principal investigator
Oslo University Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Substance Use Disorder (SUD), run by Oslo University Hospital at 1 site in Norway.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 26 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Norway. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Exit reason (time frame: On average 3 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Oct 2026; AzTrials last refreshed its copy on 26 Oct 2026.